USRE34712E - Pharmaceutically useful (+)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroiso benzofuran-5-carbonitrile and non-toxic acid addition salts thereof - Google Patents
Pharmaceutically useful (+)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroiso benzofuran-5-carbonitrile and non-toxic acid addition salts thereof Download PDFInfo
- Publication number
- USRE34712E USRE34712E US08/122,009 US12200993A USRE34712E US RE34712 E USRE34712 E US RE34712E US 12200993 A US12200993 A US 12200993A US RE34712 E USRE34712 E US RE34712E
- Authority
- US
- United States
- Prior art keywords
- compound
- fluorophenyl
- iaddend
- iadd
- carbonitrile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime, expires
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Definitions
- the present invention relates to the two novel enantiomers of the antidepressant drug 1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-.[.dihydroisobenzofuran.]. .Iadd.dihydroisobenzofuran.Iaddend.-b 5-carbonitrile (citalopram) of the following formula I: ##STR2## and to the use of these enantiomers as antidepressant compounds as well as the possible use as geriatrics or in the cure of obesity or alcoholism.
- This invention also includes pharmaceutically acceptable salts of the enantiomers of compound I formed with non-toxic organic or inorganic acids.
- Such salts are easily prepared by methods known to the art.
- the base is reacted with either the calculated amount of organic or inorganic acid in an aqueous miscible solvent, such as acetone or ethanol, with isolation of the salt by concentration and cooling or an excess of the acid in aqeuous immiscible solvent, such as ethyl ether, ethyl acetate or .[.dicloromethane.]. .Iadd.dichloromethane.Iaddend., with the desired salt separating directly. Exemplary of such organic .].salt.].
- inorganic salts are those with hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric and nitric acids.
- these salts may also be prepared by the conventional method of double decomposition of appropriate salts, which is well-known to the art.
- the invention is also concerned with a method to resolve the intermediate racemate and to produce the individual isomers of I therefrom.
- Citalopram which has been disclosed in e.g. U.S. Pat. No. 4,136,193, has proven to be an efficient antidepressant compound in man (Ref.: A. Gravem et. al., Acta pysychiat. Scan., No. 75, p. 478-486 (1987). All work in the development of this compound has been made with the racemate. Citalopram has been shown pharmacologically to be a very selective inhibitor of 5-HT reuptake. Previous attempts to crystallize diastereomeric salts of citalopram enantiomers have failed.
- the present invention also includes a new method of synthesizing I from the diol compound II by esterification of the primary alcohol group into a labile ester, which in the presence of a base undergoes spontaneous ringclosure to citalopram or, if enantiomerically pure II is esterified, the corresponding citalopram enantiomer is produced with fully conservation of stereoconfiguration.
- reaction scheme I by (+)- or (-) - ⁇ -methoxy- ⁇ -trifluoromethylphenylacetyl chloride.
- the reaction is preferably performed in an inert organic solvent as e.g. toluene, dichloromethane or tetrahydrofuran.
- a base triethylamine, N,N-dimethylaniline, pyridin or the like is added to neutralize liberated HCl.
- the diastereoisomers are subsquently separated by HPLC or fractional crystallization.
- strong base e.g. alkoxide
- an inert organic solvent as e.g. toluene, tetrahydrofuran, or dimethoxyethane yielding the pure citalopram enantiomers respectively.
- the ringclosure reaction is preferably performed at relatively low temperatures (-20° C.) to room temperature).
- (+)- ⁇ -methoxy- ⁇ -trifluoromethylacetic acid dissolved in 25 ml of chloroform were added 50 ml of thionylchloride and a few drops of dimethylformamide.
- the reaction mixture was refluxed for 2 hours.
- Excess of thionylchloride was evaporated with toluene leaving the (+)- ⁇ -methoxy- ⁇ -trifluoromethylacetyl chloride as a liquid.
- optical purity was determined by 1 H NMR spectroscopy (CDCL 3 as solvent) (Bruker AC-250 MHz instrument) by addition of a 10:1 w/w surplus of the chiral reagent (-)-2,2,2-trifluoro-1-(9-anthryl)ethanol. Optical purity: 99.6%.
- a 2:1 addition compound of the (+)-isomer with L(+)-tartaric acid was prepared in the following manner: 4 g of the (+)-isomer as base were dissolved in 100 ml of diethyl ether and extracted into 100 ml of water containing 0.8 g of L(+)-tartaric acid by stirring. The organic phase was separated and discarded. The water-phase was freeze-dried in vacuo ( ⁇ 0.1 mm Hg) for 18 hours leaving 3.8 g of a white powder of the title compound. This addition compound was stable and not hygroscopic.
- the test evaluates the ability of the substance to potentiate the effect of 5-HTP, which results in development of 5-HT syndrome (Christensen, Fjalland, Pedersen, Danneskiold-Samsoe and Svendsen; European J. Pharmacol. 41, 153-162, 1977).
- Each treatment group consists of 3 mice, and two groups are treated with the highest test dose.
- a control group only treated with 5-HTP is included and a group treated with citalopram 10 mg/kg and 5-HTP is used as reference for full 5-HT syndrome.
- 5-HTP 100 mg/kg
- injection time 5-10 sec. injection time 5-10 sec.
- 5-HTP injection time 5-10 sec.
- untreated mice remain unaffected, but if the animals have been pretreated with a substance, which inhibits the uptake of 5-HT or a 5-HT agonist, a 5-HTP syndrome will occur.
- the symptoms are the same as previously described: (1) excitation, (2) tremor, and (3) abduction of the hind limbs.
- the animals are observed for 15 minutes and each animal is given one point for each symptom present. Again the result is stated in fractions: 0/9, 1/9, . . . 9/9, where 0, 1, . . . , 9 are the number of points per group after the dose in question.
- the ED 50 value is calculated by log-probit analysis.
- the filters are placed in counting vitals and 4 ml of appropriate scintillation fluid (e.g. Picofluor ®15) are added. After shaking for 1 h and storage 2 h in the dark the content of radioactivity is determined by liquid scintillation counting. Uptake is obtained by subtracting the nonspecific binding and passive transport measured in the presence of 10 ⁇ M citalopram (Lu 10-171-B).
- appropriate scintillation fluid e.g. Picofluor ®15
- the measured cpm are plotted against drug concentration on semilogarithmic paper, and the best fitting s-shaped curve is drawn.
- the IC 50 -value is determined as the concentration, at which the uptake is 50% of the total uptake in control samples minus the nonspecific binding and uptake in the presence of 10 ⁇ M of citalopram.
- (+)-1-(3-Dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile ((+)-citalopram) and the non-toxic acid addition salts thereof may be administered to animals such as dogs, cats, horses, sheeps or the like, including human beings, both orally and parenterally, and may be used for example in the form of tablets, .[.capsles.]. .Iadd.capsules.Iaddend., powders, syrups or in the form of the usual .[.sterial.]. .Iadd.sterile .Iaddend.solutions for injection. .[.Results upon administration to human being have been very gratifying..].
- each dosage unit containing the free amine or a non-toxic acid addition salt of one of the said compounds in .[.a.]. .Iadd.an .Iaddend.amount of from about 0.10 to about 100 mg, most preferably, however, from about b 5 to 50 mg, calculated as the free amine, the total daily dosage usually ranging from about 1.0 to about 500 mg.
- the exact individual dosages as well as daily dosages in a particular case will, of course, be determined according to established medical principles under the direction of a physician.
- the .[.acitve.]. .Iadd.active .Iaddend.ingredient is for the most part mixed with ordinary tablet adjuvants such as corn starch, potato starch, talcum, magnesium stearate, gelative, lactose, gums, or the like.
- compositions .Iadd.containing (+)-citalopram in the form of an acid addition salt as the active ingredient are as follows:
- any other pharmaceutical tableting adjuvants may be used provided that they are compatible with the active ingredient, and additional compositions and dosage forms may be similar to those presently used for neuroleptics, analgesics or antidepressants.
- (+)-citalopram as well as its non-toxic acid salts with other active ingredients, especially other neuroleptics, thymoleptics, tranquilizers, analgetics or the like, fall within the scope of the present invention.
- the acid when isolating the enantiomers of citalopram in the form of an acid addition salt the acid is preferably selected so as to contain an anion which is non-toxic and pharmacologically acceptable, at least in usual therapeutic doses.
- Representative salts which are included in this preferred group are the hydrochlorides, hydrobromides, sulphates, acetates, phosphates, nitrates, methanesulphonates, ethane-sulphonates, lactates, citrates, tartrates or bitartrates, pamoates and maleates of the amines of Formula I.
- Other acids are likewise suitable and may be employed if desired.
- fumaric, benzoic, ascorbic, succinic, salicylic, bismethylenesalicylic, propionic, gluconic, malic, malonic, mandelic, .[.cannamic.]. .Iadd.cinnamic.Iaddend., citraconic, stearic, palmitic, itaconic, glycolic, benzenesulphonic, and sulphamic acids may .[.be .]. also be employed as acid addition salt-forming acids.
- the invention also comprises a method for the alleviation, palliation, mitigation or inhibition of the manifestations of certain physiological-psychological .[.abnormalies.]. .Iadd.abnormalities .Iaddend.of animals, especially depressions.Iadd., .Iaddend.by administering to a living animal body, including human beings, an adequate quantity of (+)-citalopram or a non-toxic acid addition salt thereof.
- An adequate quantity would be from about 0.001 mg to about 10 mg per kg of body weight in each unit dosage, and from about 0.003 milligrams to about 7 milligrams/kg of body weight per day.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Psychiatry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Silicon Compounds (AREA)
Abstract
The two enantiomers of the anti-depressant drug of the formula I <IMAGE> are disclosed. Methods for resolving intermediates and their [steroselective] stereoselective conversion to a corresponding [enatiomer] enantiomer of I are also disclosed.
Description
The present invention relates to the two novel enantiomers of the antidepressant drug 1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-.[.dihydroisobenzofuran.]. .Iadd.dihydroisobenzofuran.Iaddend.-b 5-carbonitrile (citalopram) of the following formula I: ##STR2## and to the use of these enantiomers as antidepressant compounds as well as the possible use as geriatrics or in the cure of obesity or alcoholism.
This invention also includes pharmaceutically acceptable salts of the enantiomers of compound I formed with non-toxic organic or inorganic acids. Such salts are easily prepared by methods known to the art. The base is reacted with either the calculated amount of organic or inorganic acid in an aqueous miscible solvent, such as acetone or ethanol, with isolation of the salt by concentration and cooling or an excess of the acid in aqeuous immiscible solvent, such as ethyl ether, ethyl acetate or .[.dicloromethane.]. .Iadd.dichloromethane.Iaddend., with the desired salt separating directly. Exemplary of such organic .].salt.]. .Iadd.salts .Iaddend.are those with maleic, fumaric, benzoic, ascorbic, pamoic, succinic, oxalic, salicylic, methanesulfonic, ethanedisulfonic, acetic, propionic, tartaric, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-amino-benzoic, glutamic, benzene sulfonic and theophylline acetic acid, as well as the 8-halotheophyllines, for example 8-bromotheophylline.
Exemplary of such inorganic salts are those with hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric and nitric acids. Of course, these salts may also be prepared by the conventional method of double decomposition of appropriate salts, which is well-known to the art.
Furthermore it was found that non-hygroscopic acid addition salts might be obtained by .[.conventinal.]. .Iadd.conventional .Iaddend.freeze drying techniques from water solutions of appropriate salts of the above mentioned kinds.
The invention is also concerned with a method to resolve the intermediate racemate and to produce the individual isomers of I therefrom.
Citalopram, which has been disclosed in e.g. U.S. Pat. No. 4,136,193, has proven to be an efficient antidepressant compound in man (Ref.: A. Gravem et. al., Acta pysychiat. Scan., No. 75, p. 478-486 (1987). All work in the development of this compound has been made with the racemate. Citalopram has been shown pharmacologically to be a very selective inhibitor of 5-HT reuptake. Previous attempts to crystallize diastereomeric salts of citalopram enantiomers have failed.
Surprisingly, it has now proven possible to resolve the intermediate .[.4-(4-dimethylamino)-1-(4'-fluorophenyl)-1-(hydroxybutyl)-3-(hydroxymethyl)benzonitrile.]. .Iadd.4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxy-1-butyl]-3-(hydroxymethyl)-benzonitrile.Iaddend., II, into its enantiomers and finally in a stereoselective way to convert these enantiomers to the corresponding citalopram enantiomers. Likewise, monoesters of II formed by optically active carboxylic acids could be separated into the corresponding diastereomers and subsequently converted directly into citalopram enantiomers in a steroselective ringclosure reaction. The intermediate diol, II, has been disclosed in e.g. U.S. Pat. No. 4,650,884 as a racemic mixture. ##STR3##
The enantiomers of the intermediate of formula II as well as monoesters fall likewise within the scope of the present invention.
Furthermore, it was shown to our surprise that almost the entire 5-HT uptake inhibition resided in the (+)-citalopram enantiomer.
The present invention also includes a new method of synthesizing I from the diol compound II by esterification of the primary alcohol group into a labile ester, which in the presence of a base undergoes spontaneous ringclosure to citalopram or, if enantiomerically pure II is esterified, the corresponding citalopram enantiomer is produced with fully conservation of stereoconfiguration.
According to the invention, II is reacted with:
(a) an enantiomerically pure acid derivative as an acid chloride, anhydride or .[.libile.]. .Iadd.labile .Iaddend.ester as e.g. .[.examplified.]. .Iadd.exemplified .Iaddend.in reaction scheme I by (+)- or (-) -α-methoxy-α-trifluoromethylphenylacetyl chloride. The reaction is preferably performed in an inert organic solvent as e.g. toluene, dichloromethane or tetrahydrofuran. A base (triethylamine, N,N-dimethylaniline, pyridin or the like) is added to neutralize liberated HCl. The diastereoisomers are subsquently separated by HPLC or fractional crystallization. The thus purified .[.disatereoisomers.]. .Iadd.diastereoisomers.Iaddend.are .[.finnaly.]. .Iadd.finally .Iaddend.separately treated with strong base (e.g. alkoxide) in an inert organic solvent as e.g. toluene, tetrahydrofuran, or dimethoxyethane yielding the pure citalopram enantiomers respectively. The ringclosure reaction is preferably performed at relatively low temperatures (-20° C.) to room temperature). ##STR4## (b) the enantiomers of an optically active acid successively affording the pure diastereomeric salts. Optically antipodes of tartaric acid, di-benzoyltartaric acid, di-(p-.[.toloyl.]. .Iadd.toluoyl.Iaddend.)tartaric acid, bisnaphthylphosphoric acid, 10-camphorsulphonic acid and the like are conveniently used.
(c) Stereoselective ringclosure of the pure enantiomers of II prepared as in (b) is performed via a labile ester as e.g. methansulfonyl, p-toluenesulfonyl, 10-camphorsulfonyl, trifuoracetyl or trifluoromethansulfonyl with simultaneous addition of a base (triethylamine, dimethylaniline or pyridin) in an inert organic solvent at 0° C. The ringclosure reaction is .[.examplified.]. .Iadd.exemplified .Iaddend.in reaction scheme II: ##STR5##
To 11 g of (+)-α-methoxy-α-trifluoromethylacetic acid dissolved in 25 ml of chloroform were added 50 ml of thionylchloride and a few drops of dimethylformamide. The reaction mixture was refluxed for 2 hours. Excess of thionylchloride was evaporated with toluene leaving the (+)-α-methoxy-α-trifluoromethylacetyl chloride as a liquid. This liquid diluted with 50 ml of dichloromethane was added dropwise to an ice cooled solution of 17 gr of .[.4-(4-dimethylamino-1-(4'-fluorophenyl)-1-hydroxybutyl)-3-(hydroxymethyl)-benzonitrile.]. .Iadd.4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxy-1-butyl]-3-(hydroxymethyl)-benzonitrile.Iaddend., II, and 8 ml of triethylamine in 150 ml of dichloromethane. The reaction mixture was further stirred for another hour at room temperature, subsequently washed with brine, dried (MgSO4) and the solvent evaporated below 30° C. in vacuo affording 29 gr of the ester as a diastereomeric mixture. By repeated HPLC purification (eluted with ethyl acetate/tetrahydrofuran 9:1 containing 4% of triethylamine) and by collecting only the 5-10% initial substance in the main peak, 1.1 gr of enantiomerically pure compound was isolated.
The substance thus isolated was dissolved in dry toluene (50 ml) and added to a suspension of 0.3 gr of potassium t-butoxide in 20 ml of toluene at 0° C. The toluene solution was washed with water, dried (MgSO4) and the solvent evaporated yielding 0.6 gr of (+)-1-(dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile as an oil. [α]D =+11.81° (c=1, CH3 OH) (determined with a substance containing 10% w/w of methanol). The optical purity was determined by 1 H NMR spectroscopy (CDCL3 as solvent) (Bruker AC-250 MHz instrument) by addition of a 10:1 w/w surplus of the chiral reagent (-)-2,2,2-trifluoro-1-(9-anthryl)ethanol. Optical purity: 99.6%.
In a totally analogous way the (-)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile was synthesized. [α]D =-12.34° (c=1, CH3 OH) (determined with a substance containing 10% w/w of methanol). Optical purity: 99.0%.
To a solution of 85 gr of .[.4-(4-dimethylamino)-1-4'-fluorophenyl)-1-(hydroxybutyl)-3-(hydroxymethyl)-benzonitrile.]. .Iadd.4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxy-1-butyl]-3-(hydroxymethyl)-benzonitrile.Iaddend., hydrobromide in 500 ml of water were added 200 ml of ice cooled 2M NaOH solution and 500 ml of ether. The mixture was stirred for 1/2 hour, the ether phase separated, dried (MgSO4) and the ether evaporated. The remaining oil was dissolved in 400 ml of 2-propanol at 40° C., and 40 gr of (+)-di-p-.[.toloyltartaric.]..Iadd.toluoyltartaric .Iaddend.acid (as hydrate) were added under vigorous stirring. After a short while crystallization began. After 3 hours of stirring the precipatated salt was filtered off and dried yielding 29.2 gr (55.1%) of .[.(-)-4-(4-dimethylamino)-1-(4'fluorophenyl)-1-(hydroxybutyl)- 3-(hydroxymethyl)benzonitrile.]. .Iadd.(-)-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxy-1-butyl]-3-(hydroxymethyl)benzonitrile.Iaddend., hemi (+)-di-p-.[.toloyltartaric.]. .Iadd.toluoyltartaric .Iaddend.acid salt. MP: 134°-135° C., [α]D =+10.0° (c=1, CH3 OH). The filtrate is used below.
To an ice cooled solution of 14 gr of the (-)-isomer from above as a base in 300 ml of dry toluene were added 16 ml of triethylamine, and 3.6 ml of methansulfonyl chloride in 20 ml of dry toluene were added dropwise during 10 minutes. The reaction mixture was further stirred for 1/2 hour, washed with brine, dried (MgSO4) and the solvent evaporated. The title compound was purified by column chromatography affording 8 g of (+)-1-(3-dimethylaminopropyl)-1-(4'-.[.flurophenyl.]. .Iadd.fluorophenyl.Iaddend.-1,3-dihydroisobenzofuran-5-carbonitrile. [α]D =+12.33° (c=1, CH3 OH). The oxalic acid salt of the (+)-isomer crystallized from acetone. MP: 147°-148° C., [α]D =+12.31° (c=1, CH3 OH).
The pamoic acid salt of the (+)-isomer was prepared in the following manner: To 1.8 g of the base of the (+)-isomer was added 2 g of pamoic acid in 25 ml of MeOH. The mixture was refluxed for an hour and subsequently colled to room temperature. The precipitate was filtered off yielding 3.0 g of the pamoic acid salt. MP: 264°-266° C., [α]D =+13.88° C. (c=1, dimethylformamide).
A 2:1 addition compound of the (+)-isomer with L(+)-tartaric acid was prepared in the following manner: 4 g of the (+)-isomer as base were dissolved in 100 ml of diethyl ether and extracted into 100 ml of water containing 0.8 g of L(+)-tartaric acid by stirring. The organic phase was separated and discarded. The water-phase was freeze-dried in vacuo (<0.1 mm Hg) for 18 hours leaving 3.8 g of a white powder of the title compound. This addition compound was stable and not hygroscopic.
In a corresponding manner as above via the .[.(+)-4-(4-dimethylamino)-1-(4'-fluorophenyl)-1-(hydroxybutyl)-3-(hydroxymethyl)benezonitrile.]. .Iadd.(+)-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxy-1-butyl]-3-(hydroxymethyl)-benzonitrile.Iaddend., hemi (-)-di-(p-toloyl)tartaric acid salt ([α]D =-8.9° (c=1, CH3 OH)) which was converted to the corresponding diol base ([α]D =+61.1° (c=1, CH3 OH)) and finally ringclosure reaction yielded 10 gr of (-)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile. [α]D =-12.1° (c=1, CH3 OH).
The oxalic acid salt of the (-)-isomer crystallized from acetone, MP: 147°-148° C., [α]D =-12.08° (c=1, CH3 OH).
To an ice cooled solution of 28 gr of racemic diol base, II, in 500 ml of dichloromethane were added 32 ml of triethylamine, and 7.5 ml of methansulfonyl chloride in 30 ml of dichloromethane were added dropwise during a half hour. The reaction mixture was washed with 0.1M NaOH solution twice, the organic phase separated, dried (MgSO4) and the solvent evaporated, leaving 21.5 gr of the title (±)-citalopram as a crystalline base. The thus obtained material was dissolved in a mixture of 2-propanol and methanol (2:1) and an equivalent amount of gaseous HBr was introduced. The mixture was left overnight and the precipitated hydrobromide was filtered off. Yield: 26 gr with MP 184°-186° C.
The enantiomers from Example 1 were tested for their ability to block 5-HT reuptake in standard and reliable test method. Results are shown in Table I in comparison with the racemic mixture of citalopram.
The test evaluates the ability of the substance to potentiate the effect of 5-HTP, which results in development of 5-HT syndrome (Christensen, Fjalland, Pedersen, Danneskiold-Samsoe and Svendsen; European J. Pharmacol. 41, 153-162, 1977).
Each treatment group consists of 3 mice, and two groups are treated with the highest test dose. A control group only treated with 5-HTP is included and a group treated with citalopram 10 mg/kg and 5-HTP is used as reference for full 5-HT syndrome.
30 minutes after the administration of the test substance, the other groups are given 5-HTP (100 mg/kg) i.v. (injection time 5-10 sec.). After this 5-HTP dose normal, untreated mice remain unaffected, but if the animals have been pretreated with a substance, which inhibits the uptake of 5-HT or a 5-HT agonist, a 5-HTP syndrome will occur. The symptoms are the same as previously described: (1) excitation, (2) tremor, and (3) abduction of the hind limbs. The animals are observed for 15 minutes and each animal is given one point for each symptom present. Again the result is stated in fractions: 0/9, 1/9, . . . 9/9, where 0, 1, . . . , 9 are the number of points per group after the dose in question. The ED50 value is calculated by log-probit analysis.
By this method the inhibition by drugs of the uptake of .[.3 H-serotonin.]. .Iadd.3 H-serotonin .Iaddend.(3 H-5-HT)(10 nm) in rat brain synaptosomes is determined in vitro. Method and results in Hyttel, Psychopharmacology 1978, 60, 13-18; Hyttel, Prog. Neuro-Psychopharmacol. & Biol. .[.Psychait..]. .Iadd.Psychiat. .Iaddend.1982, 6,277-295; Hyttel & Larsen, Acta pharmacol. tox. 1985, 56, suppl. 1, 146-153. .[.Procedure p.].
Male Wistar (Mol: Wist) rats (125-250 g) are sacrified by decapitation and .[.exanguinated.]. .Iadd.exsanguinated .Iaddend.Brain tissue (minus cerebellum) is gently homogenized (glass teflon homogenizer) in 40 vol (w/v) of ice cold 0.32M of sucrose containing 1 mM of nialamide. The P2 fraction (synaptosomal fraction) is obtained by centrifugation (600 g. 10 min and 25000 g. 55 min, 4° C.) and suspended in 800 volumes of a modified Krebs-Ringer-phosphate buffer, pH 7.4.
To 4000 μl of the synaptosomal suspension (5 mg original tissue) on ice are added 100 μl test substance in water. After preincubation at 37° C. for 5 min, 100 μl of 3 H-1-NA (final .[.concnetration.]. .Iadd.concentration .Iaddend.10 nM) are added and the samples are incubated for 10 min at 37° C. The incubation is terminated by filtering the samples under vacuum through .[.Whatmam.]. .Iadd.Whatman .Iaddend.GF/F filters with a wash of 5 ml buffer containing 10 μM of unlabeled 5-HT. The filters are placed in counting vitals and 4 ml of appropriate scintillation fluid (e.g. Picofluor ®15) are added. After shaking for 1 h and storage 2 h in the dark the content of radioactivity is determined by liquid scintillation counting. Uptake is obtained by subtracting the nonspecific binding and passive transport measured in the presence of 10 μM citalopram (Lu 10-171-B).
For determination of the inhibition of uptake five concentrations of drugs covering 3 decades are used.
The measured cpm are plotted against drug concentration on semilogarithmic paper, and the best fitting s-shaped curve is drawn. The IC50 -value is determined as the concentration, at which the uptake is 50% of the total uptake in control samples minus the nonspecific binding and uptake in the presence of 10 μM of citalopram.
TABLE 1 ______________________________________ PHARMACOLOGICAL TEST RESULTS ______________________________________ 5-HTP pot. 5-HT uptake inhibition Compound ED.sub.50 μmol/kg IC.sub.50 (nM) ______________________________________ (+)-citalopram 2.0 1.1 (-)-citalopram 120 150 (±)-citalopram 3.3 1.8 ______________________________________
(+)-1-(3-Dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile ((+)-citalopram) and the non-toxic acid addition salts thereof may be administered to animals such as dogs, cats, horses, sheeps or the like, including human beings, both orally and parenterally, and may be used for example in the form of tablets, .[.capsles.]. .Iadd.capsules.Iaddend., powders, syrups or in the form of the usual .[.sterial.]. .Iadd.sterile .Iaddend.solutions for injection. .[.Results upon administration to human being have been very gratifying..].
Most conveniently the compounds of Formula I are administered orally in unit dosage form such as tablets or capsules, each dosage unit containing the free amine or a non-toxic acid addition salt of one of the said compounds in .[.a.]. .Iadd.an .Iaddend.amount of from about 0.10 to about 100 mg, most preferably, however, from about b 5 to 50 mg, calculated as the free amine, the total daily dosage usually ranging from about 1.0 to about 500 mg. The exact individual dosages as well as daily dosages in a particular case will, of course, be determined according to established medical principles under the direction of a physician.
When preparing tablets, the .[.acitve.]. .Iadd.active .Iaddend.ingredient is for the most part mixed with ordinary tablet adjuvants such as corn starch, potato starch, talcum, magnesium stearate, gelative, lactose, gums, or the like.
Typical examples of formulas for .[.composition.]. .Iadd.compositions .Iaddend.containing (+)-citalopram in the form of an acid addition salt as the active ingredient, are as follows:
______________________________________ (1) Tablets containing 5 milligrams of (+)-citalopram calculated as the free base: Compound 20 5 mg Lactose 18 mg Potato starch 27 mg Saccharose 58 mg Sorbitol 3 mg Talcum 5 mg Gelatine 2 mg Povidone 1 mg Magnesium stearate 0.5 mg (2) Tablets containing 50 milligrams of (+)-citalopram calculated as the free base: (+)-citalopram 50 mg Lactose 16 mg Potato starch 45 mg Saccharose 106 mg Sorbitol 6 mg Talcum 9 mg Gelatine 4 mg Povidone 3 mg Magnesium stearate 0.6 mg (3) Syrup containing per milliliter: (+)-citalopram 10 mg Sorbitol 500 mg Tragacanth 7 mg Glycerol 50 mg Methyl-paraben 1 mg Propyl-paraben 0.1 mg Ethanol 0.005 ml Water ad 1 ml (4) Solution for injection containing per milliliter: (+)-citalopram 50 mg Acetic acid 17.9 mg Sterile water ad 1 ml (5) Solution for injection containing per milliliter: (+)-citalopram 10 mg Sorbitol 42.9 mg Acetic acid 0.63 mg Sodium hydroxide 22 mg Sterile water ad 1 ml ______________________________________
Any other pharmaceutical tableting adjuvants may be used provided that they are compatible with the active ingredient, and additional compositions and dosage forms may be similar to those presently used for neuroleptics, analgesics or antidepressants.
Also combinations of (+)-citalopram as well as its non-toxic acid salts with other active ingredients, especially other neuroleptics, thymoleptics, tranquilizers, analgetics or the like, fall within the scope of the present invention.
As previously stated, when isolating the enantiomers of citalopram in the form of an acid addition salt the acid is preferably selected so as to contain an anion which is non-toxic and pharmacologically acceptable, at least in usual therapeutic doses. Representative salts which are included in this preferred group are the hydrochlorides, hydrobromides, sulphates, acetates, phosphates, nitrates, methanesulphonates, ethane-sulphonates, lactates, citrates, tartrates or bitartrates, pamoates and maleates of the amines of Formula I. Other acids are likewise suitable and may be employed if desired. For example: fumaric, benzoic, ascorbic, succinic, salicylic, bismethylenesalicylic, propionic, gluconic, malic, malonic, mandelic, .[.cannamic.]. .Iadd.cinnamic.Iaddend., citraconic, stearic, palmitic, itaconic, glycolic, benzenesulphonic, and sulphamic acids may .[.be .]. also be employed as acid addition salt-forming acids.
When it is desired to isolate a compound of the invention in the form of the free base, this may be done according to conventional procedure as by dissolving the isolated or unisolated salt in water, treating with a suitable alkaline material, extracting the liberated free base with a suitable organic .[.solvent.]. .Iadd.solvent,.Iaddend.drying the extract and evaporating to dryness or fractionally distilling to effect isolation of the free basic amine.
The invention also comprises a method for the alleviation, palliation, mitigation or inhibition of the manifestations of certain physiological-psychological .[.abnormalies.]. .Iadd.abnormalities .Iaddend.of animals, especially depressions.Iadd., .Iaddend.by administering to a living animal body, including human beings, an adequate quantity of (+)-citalopram or a non-toxic acid addition salt thereof. An adequate quantity would be from about 0.001 mg to about 10 mg per kg of body weight in each unit dosage, and from about 0.003 milligrams to about 7 milligrams/kg of body weight per day.
It is to be understood that the invention is not limited to the exact details of operation or exact .[.compound.]. .Iadd.compounds .Iaddend.or compositions shown and described, as obvious modifications and equivalents will be apparent to one skilled in the art.
Claims (12)
1. A compound selected from substantially pure (+)-1-(3-Dimethylaminopropyl)-1-(4'- fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile and non-toxic acid addition salts thereof.
2. A compound of claim 1 being .Iadd.the .Iaddend.pamoic acid salt of substantially pure (+)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile.
3. A pharmaceutical composition in unit dosage form comprising a pharmaceutically acceptable diluent or adjuvant and, as an active ingredient, a compound as defined in claim 1.
4. A pharmaceutical composition in unit dosage form comprising a pharmaceutically acceptable diluent or adjuvant and, as an active ingredient, the compound of claim 2.
5. A pharmaceutical composition in unit dosage form, according to claim 3, wherein the active ingredient is present in an amount from 0.1 to 100 milligram per unit dose.
6. A pharmaceutical composition in unit dosage form, according to claim 4, wherein the active ingredient is present in an amount from 0.1 to 100 milligram per unit dose.
7. A method for the alleviation of depression in a living animal body subject thereto which comprises the step of administering to the living animal body an amount of a compound of claim 1 which is effective for said purpose.
8. A method for the alleviation of depression in a living animal body subject thereto which comprises the step of administering to the living animal body an amount of a compound of claim 2 which is effective for said purpose.
9. Method of claim .[.10.]. .Iadd.7 .Iaddend.wherein the compound is administered in the form of a pharmaceutical composition thereof.
10. Method of claim 8 wherein the compound is administered in the form of a pharmaceutical composition thereof.
11. A method for the preparation of a compound as defined in claim 1, which comprises, converting substantially, pure .[.(+)-4-(4-dimethylamino)-1-(4'-fluorophenyl)-1-(hydroxybutyl)-3-(hydroxymethyl)-benzonitrile.]. .Iadd.(-)-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxy-1-butyl]-3-(hydroxymethyl)-benzonitrile .Iaddend.or a .[.monomester.]. .Iadd.monoester .Iaddend.thereof in a stereoselective way to substantially pure (+)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile which is isolated as such or as a non-toxic acid addition salt thereof.
12. A compound of the formula .Iadd.(31)-Enantiomer of the compound 4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxy-1-butyl]-3-(hydroxymethyl)-benzonitrile or an ester of said (-)enantiomer, which has the formula .Iaddend. ##STR6## wherein R is hydrogen or represents a group completing a labile ester.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB888814057A GB8814057D0 (en) | 1988-06-14 | 1988-06-14 | New enantiomers & their isolation |
GB8814057 | 1988-06-14 | ||
US07/363,589 US4943590A (en) | 1988-06-14 | 1989-06-08 | Pharmaceutically useful (+)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydrosobenzofuran-5-carbonitrile and non-toxic acid addition salts thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US07/363,589 Reissue US4943590A (en) | 1988-06-14 | 1989-06-08 | Pharmaceutically useful (+)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydrosobenzofuran-5-carbonitrile and non-toxic acid addition salts thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE34712E true USRE34712E (en) | 1994-08-30 |
Family
ID=10638616
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US07/363,589 Ceased US4943590A (en) | 1988-06-14 | 1989-06-08 | Pharmaceutically useful (+)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydrosobenzofuran-5-carbonitrile and non-toxic acid addition salts thereof |
US08/122,009 Expired - Lifetime USRE34712E (en) | 1988-06-14 | 1993-09-14 | Pharmaceutically useful (+)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroiso benzofuran-5-carbonitrile and non-toxic acid addition salts thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US07/363,589 Ceased US4943590A (en) | 1988-06-14 | 1989-06-08 | Pharmaceutically useful (+)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydrosobenzofuran-5-carbonitrile and non-toxic acid addition salts thereof |
Country Status (24)
Country | Link |
---|---|
US (2) | US4943590A (en) |
EP (1) | EP0347066B1 (en) |
JP (2) | JP3044253B2 (en) |
AT (1) | ATE119896T1 (en) |
AU (1) | AU623144B2 (en) |
CA (2) | CA1339452C (en) |
CY (2) | CY2081B1 (en) |
DE (2) | DE68921672T2 (en) |
DK (2) | DK259989A (en) |
ES (1) | ES2068891T4 (en) |
FI (4) | FI98627C (en) |
GB (1) | GB8814057D0 (en) |
GR (1) | GR3015889T3 (en) |
HK (1) | HK139596A (en) |
HU (1) | HU211460A9 (en) |
IE (1) | IE65734B1 (en) |
IL (1) | IL90465A (en) |
LU (1) | LU90999I2 (en) |
MX (1) | MX9203346A (en) |
NL (1) | NL300155I2 (en) |
NO (2) | NO172892C (en) |
NZ (1) | NZ229426A (en) |
PT (1) | PT90845B (en) |
ZA (1) | ZA894476B (en) |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6579993B2 (en) | 2001-01-30 | 2003-06-17 | Orion Corporation, Fermion | Process for the preparation of 1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile |
US20040009573A1 (en) * | 2002-01-30 | 2004-01-15 | Gary Strobel | Pestalotiopsis microsporia isolates and compounds derived therefrom |
US20040029956A1 (en) * | 1999-07-08 | 2004-02-12 | H. Lundbeck A/S | Treatment of neurotic disorders |
US20040132808A1 (en) * | 2000-03-13 | 2004-07-08 | Hans Petersen | Crystalline base of citalopram |
US20040192766A1 (en) * | 2001-05-01 | 2004-09-30 | H. Lundbeck A/S | Use of enantiomeric pure escitalopram |
US20050043550A1 (en) * | 2002-01-07 | 2005-02-24 | Thennati Rajamannar | Process for the preparation of 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran carbonitrile |
US20050101666A1 (en) * | 2003-11-07 | 2005-05-12 | H. Lundbeck A/S | Method of treating premenstrual dysphoric disorder with escitalopram |
US20050143350A1 (en) * | 2003-11-19 | 2005-06-30 | Seed John C. | Combination drug therapy to treat obesity |
US20050196453A1 (en) * | 2004-03-05 | 2005-09-08 | H. Lundbeck A/S | Crystalline composition containing escitalopram |
US20060014957A1 (en) * | 2004-07-07 | 2006-01-19 | Pfizer Inc | Resolution of an aryl-fused azapolycyclic compound |
WO2006021971A2 (en) | 2004-08-23 | 2006-03-02 | Sun Pharmaceutical Industries Limited | 'process for preparation of citalopram and enantiomers' |
US7019153B2 (en) | 2003-06-10 | 2006-03-28 | Sun Pharmaceutical Industries Limited | Process for hydrogenolysis of [1-(3-dimethylamino)propyl)]-1-(4-fluorophenyl)-1,3-dihydro-5-halo-isobenzofuran acetamido-3-substituted-3-cephem-4-carboxylic acid |
US20060247276A1 (en) * | 2005-04-22 | 2006-11-02 | Wyeth | Benzofuranyl alkanamine derivatives and uses thereof |
US20060258739A1 (en) * | 2005-04-22 | 2006-11-16 | Wyeth | Dihydrobenzofuran derivatives and uses therof |
US20060258714A1 (en) * | 2005-04-22 | 2006-11-16 | Wyeth | Chromane and chromene derivatives and uses thereof |
US20070021499A1 (en) * | 2005-06-22 | 2007-01-25 | H. Lundbeck A/S | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base |
US20070112075A1 (en) * | 2005-10-14 | 2007-05-17 | Forest Laboratories, Inc. | Stable pharmaceutical formulations containing escitalopram and bupropion |
US20070190624A1 (en) * | 2004-02-12 | 2007-08-16 | H. Lundbeck A/S | Method for the separation of intermediates which may be used for the preparation of escitalopram |
US20070203231A1 (en) * | 2005-10-14 | 2007-08-30 | Forest Laboratories, Inc. | Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion |
US20070225279A1 (en) * | 2006-03-24 | 2007-09-27 | Wyeth | Therapeutic combinations for the treatment of depression |
US20080153832A1 (en) * | 2006-12-22 | 2008-06-26 | Allergan, Inc. | Pan-alpha-2 receptor agonist and relaxant compositions for treating gastrointestinal motility disorders |
US20080153881A1 (en) * | 2006-12-22 | 2008-06-26 | Allergan, Inc. | Alpha-2b receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders |
US20080153808A1 (en) * | 2006-12-22 | 2008-06-26 | Allergan, Inc. | Alpha-2 receptor pan agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain |
US20080153927A1 (en) * | 2006-12-22 | 2008-06-26 | Allergan, Inc. | Alpha-2b receptor agonist and relaxant compositions for treating gastrointestinal motility disorders |
US20080153825A1 (en) * | 2006-12-22 | 2008-06-26 | Allergan Inc. | Alpha-2b receptor agonist and 5ht4 serotonin receptor compositions for treating gastrointestinal motility disorders |
US20080153880A1 (en) * | 2006-12-22 | 2008-06-26 | Allergan, Inc. | Pan-alpha-2 receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders |
US20080153874A1 (en) * | 2006-12-22 | 2008-06-26 | Allergan Inc. | Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain |
US7402687B2 (en) | 2005-04-22 | 2008-07-22 | Wyeth | Dihydrobenzofuran derivatives and uses thereof |
US20080177096A1 (en) * | 2004-08-23 | 2008-07-24 | Sun Pharmaceutical Industries Ltd. | Process for preparation of citalopram and enantiomers |
EP1988086A1 (en) | 2007-04-23 | 2008-11-05 | Synthon B.V. | Process for resolving citalopram via its (S)-enriched citalopram tartrate compound. |
US20090036468A1 (en) * | 2007-08-03 | 2009-02-05 | Forest Laboratories Holdings Limited | Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands |
US20090099375A1 (en) * | 2005-07-27 | 2009-04-16 | Vipin Kumar Kaushik | process for the preparation of escitalopram |
US20100249438A1 (en) * | 2009-03-30 | 2010-09-30 | Vijaya Bhaskar Bolugoddu | Preparation of escitalopram |
WO2013114416A1 (en) | 2012-01-30 | 2013-08-08 | Carthesia S.A.S. | Lyophilized tablets of escitalopram oxalate for sublingual administration |
US8829020B2 (en) | 2009-07-16 | 2014-09-09 | Mallinckrodt Llc | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers |
Families Citing this family (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5322851A (en) * | 1990-07-02 | 1994-06-21 | H. Lundbeck A/S | Indole derivatives |
US5665270A (en) * | 1991-05-20 | 1997-09-09 | Chisso Corporation | Optically active trifluorolactic acid derivative and liquid crystal composition |
DK78692D0 (en) * | 1992-06-12 | 1992-06-12 | Lundbeck & Co As H | DIMER PIPERIDINE AND PIPERAZINE DERIVATIVES |
DE4439836C1 (en) * | 1994-11-08 | 1996-06-05 | Hoechst Ag | cis-4- (2,2,3,3-tetrafluoropropoxy) -cinnamonitrile and trans-4- (2,2,3,3-tetrafluoropropoxy) -cinnamonitrile and a process for their preparation |
UA62985C2 (en) * | 1997-11-10 | 2004-01-15 | Lunnbeck As H | A method for the preparation of citalopram |
PL199423B1 (en) * | 1998-10-20 | 2008-09-30 | Lundbeck & Co As H | Method for the preparation of citalopram |
PT1140886E (en) | 1998-12-23 | 2003-08-29 | Lundbeck & Co As H | METHOD FOR THE PREPARATION OF 5-CYANOFALIDE |
AR022329A1 (en) | 1999-01-29 | 2002-09-04 | Lundbeck & Co As H | METHOD FOR THE PREPARATION OF 5-CYANOFTALIDE |
BR9917346A (en) * | 1999-04-14 | 2002-02-26 | Lundbeck & Co As H | Method for preparing intermediate citalopram and using it |
US6245782B1 (en) | 1999-05-17 | 2001-06-12 | Heartdrug Research L.L.C. | Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors |
ITMI991579A1 (en) | 1999-06-25 | 2001-01-15 | Lundbeck & Co As H | METHOD FOR THE PREPARATION OF CITALOPRAM |
ITMI991581A1 (en) * | 1999-06-25 | 2001-01-15 | Lundbeck & Co As H | METHOD FOR THE PREPARATION OF CITALOPRAM |
US6403657B1 (en) | 1999-10-04 | 2002-06-11 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity |
US6759437B2 (en) | 1999-10-04 | 2004-07-06 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity including cysteine |
ATE277032T1 (en) * | 1999-10-25 | 2004-10-15 | Lundbeck & Co As H | METHOD FOR PRODUCING CITALOPRAM |
GB2360281B (en) * | 1999-10-25 | 2002-01-16 | Lundbeck & Co As H | Method for the preparation of citalopram |
AR026063A1 (en) | 1999-11-01 | 2002-12-26 | Lundbeck & Co As H | METHOD FOR THE PREPARATION OF 5-CARBOXIFTALIDA. |
UA77650C2 (en) * | 1999-12-06 | 2007-01-15 | Lundbeck & Co As H | Use of serotonin reuptake inhibitor in combination with deramcyclane |
MXPA02006503A (en) | 1999-12-28 | 2002-12-09 | Lundbeck & Co As H | Method for the preparation of citalopram. |
CA2397270C (en) * | 2000-01-14 | 2007-08-21 | H. Lundbeck A/S | Method for the preparation of 5-cyanophthalide |
FR2805812A1 (en) | 2000-02-24 | 2001-09-07 | Lundbeck & Co As H | PROCESS FOR THE PREPARATION OF CITALOPRAM |
IES20010157A2 (en) * | 2000-03-03 | 2002-03-06 | Lundbeck & Co As H | Method for the preparation of citalopram |
GB0005477D0 (en) | 2000-03-07 | 2000-04-26 | Resolution Chemicals Limited | Process for the preparation of citalopram |
NZ521201A (en) * | 2000-03-13 | 2004-02-27 | H | Method for the preparation of citalopram |
TR200202195T2 (en) * | 2000-03-13 | 2002-12-23 | H. Lundbeck A/S | Step-alkylation of 5-substituted 1- (4-fluorophenyl) -1,3- dihydroisobenzofuran |
IES20010206A2 (en) | 2000-03-13 | 2002-03-06 | Lundbeck & Co As H | Method for the preparation of citalopram |
CN1418205A (en) | 2000-03-14 | 2003-05-14 | H·隆德贝克有限公司 | method for preparation of citalopram |
IL151487A0 (en) * | 2000-03-16 | 2003-04-10 | Lundbeck & Co As H | Method for the preparation of 5-cyano-1-(4-flourophenyl)-1,3-dihydroisobenzofurans |
AR032455A1 (en) | 2000-05-12 | 2003-11-12 | Lundbeck & Co As H | METHOD FOR THE PREPARATION OF CITALOPRAM, AN INTERMEDIARY EMPLOYED IN THE METHOD, A METHOD FOR THE PREPARATION OF THE INTERMEDIARY EMPLOYED IN THE METHOD AND PHARMACEUTICAL COMPOSITION ANTIDEPRESSIVE |
EA008373B1 (en) * | 2000-07-07 | 2007-04-27 | Х. Лундбекк А/С | Use of escitalopram useful in the treatment of disorders associated with post traumatic stress disorder |
EA008372B1 (en) * | 2000-07-07 | 2007-04-27 | Х.Лундбекк А/С | Use of escitalopram for treating disorders associated with social anxiety disorder |
AU7090201A (en) * | 2000-07-20 | 2002-02-05 | Lauras As | Method |
CA2353693C (en) * | 2000-08-10 | 2003-07-22 | H. Lundbeck A/S | Pharmaceutical composition containing citalopram |
IL144816A (en) | 2000-08-18 | 2005-09-25 | Lundbeck & Co As H | Method for the preparation of citalopram |
US20030232881A1 (en) * | 2000-10-27 | 2003-12-18 | H. Lundbeck A/S | Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them |
US20030109577A1 (en) * | 2000-10-27 | 2003-06-12 | Ken Liljegren | Pharmaceutical composition containing citalopram |
CN1366526A (en) * | 2000-12-28 | 2002-08-28 | H·隆德贝克有限公司 | Process for preparation of pure citalopram |
BG65271B1 (en) * | 2001-06-18 | 2007-11-30 | H. Lundbeck A/S | Method for the preparation of citalopram |
AR034612A1 (en) * | 2001-06-25 | 2004-03-03 | Lundbeck & Co As H | PROCESS FOR THE PREPARATION OF RACEMIC CITALOPRAM AND / OR OF THE S- OR R-CITALOPRAM THROUGH THE SEPARATION OF A MIXING OF R- AND S-CITALOPRAM |
AR034759A1 (en) * | 2001-07-13 | 2004-03-17 | Lundbeck & Co As H | METHOD FOR THE PREPARATION OF ESCITALOPRAM |
DK1522539T3 (en) * | 2001-07-31 | 2007-05-07 | Lundbeck & Co As H | Crystalline composition containing excitalopram |
ES2234797T3 (en) * | 2001-08-02 | 2005-07-01 | Infosint Sa | PROCEDURE FOR THE PREPARATION OF CITALOPRAM FROM 5-FORMILFTALIDA. |
IS7239A (en) * | 2001-12-14 | 2004-04-29 | H. Lundbeck A/S | Process for the production of acitalopram |
EP1346989A1 (en) * | 2002-03-21 | 2003-09-24 | Jubilant Organosys Limited | Improved process for the preparation of citalopram and its hydrobromide |
CA2381341A1 (en) * | 2002-04-09 | 2003-10-09 | Torcan Chemical Ltd. | Process and intermediates for preparing escitalopram |
FI20021421A0 (en) * | 2002-07-30 | 2002-07-30 | Orion Corp Fermion | Production Process |
PE20040991A1 (en) * | 2002-08-12 | 2004-12-27 | Lundbeck & Co As H | SEPARATION OF INTERMEDIARIES FOR THE PREPARATION OF ESCITALOPRAM |
US6812355B2 (en) | 2002-10-22 | 2004-11-02 | Sekhsaria Chemicals Limited | Process for the manufacture of citalopram hydrobromide from 5-bromophthalide |
US20050137255A1 (en) * | 2002-12-23 | 2005-06-23 | H. Lundbeck A/S | Crystalline escitalopram hydrobromide and methods for preparing the same |
EP2363389A1 (en) | 2002-12-23 | 2011-09-07 | H. Lundbeck A/S | A process for the preparation of racemic citalopram diol and/or S- or R-citalopram diols and the use of such diols for the preparation of racemic citalopram, R-citalopram and/or S-citalopram |
ES2298595T3 (en) * | 2002-12-23 | 2008-05-16 | H. Lundbeck A/S | ESCITALOPRAM HYDROBROMIDE AND A METHOD FOR PREPARATION. |
TWI331605B (en) * | 2002-12-23 | 2010-10-11 | Lundbeck & Co As H | A process for the preparation of racemic citalopram diol and/or s- or r-citalopram diols and the use of such diols for the preparation of racemic citalopram, r-citalopram and/or s-citalopram |
CA2519629A1 (en) * | 2003-03-21 | 2004-09-30 | H. Lundbeck A/S | Intermediates for the preparation of citalopram and escitalopram |
TR200504022T1 (en) * | 2003-03-24 | 2006-08-21 | Hetero Drugs Limited | New liquid crystal forms of (S) -sitalopram oxalate. |
RU2320369C2 (en) | 2003-09-12 | 2008-03-27 | Пфайзер Инк. | Combinations containing alpha-2-delta ligands and serotonin/noradrenaline reuptake inhibitors |
ES2228274B1 (en) * | 2003-09-24 | 2006-06-01 | Astur Pharma, S.A. | CHEMIOENZYMATIC SYNTHESIS OF (+) - CITALOPRAM AND (-) - CITALOPRAM. |
DK1506963T3 (en) * | 2003-10-28 | 2005-08-01 | Adorkem Technology Spa | Process for the preparation of citalopram |
EP1706394B1 (en) * | 2003-11-12 | 2014-12-17 | Dr. Reddy's Laboratories, Inc. | Preparation of escitalopram |
US20050107466A1 (en) * | 2003-11-17 | 2005-05-19 | H. Lundbeck A/S | Method of treating or reducing suicidal thoughts with escitalopram |
AU2003282383A1 (en) * | 2003-11-20 | 2005-06-08 | Natco Pharma Limited | A process for the preparation of high purity escitalopram |
CN100569765C (en) * | 2003-12-19 | 2009-12-16 | 杭州民生药业集团有限公司 | Citalopram intermediate crystalline base |
NZ549100A (en) * | 2004-03-05 | 2010-02-26 | Lundbeck & Co As H | Crystalline composition containing escitalopram oxalate |
ITMI20040717A1 (en) | 2004-04-09 | 2004-07-09 | Adorkem Technology Spa | CHEMO-ENZYMATIC PROCEDURE FOR THE PREPARATION OF ESCITALOPRAM |
CA2567249A1 (en) * | 2004-04-19 | 2006-10-05 | Jds Pharmaceuticals, Llc | Lithium combinations, and uses related thereto |
PE20060437A1 (en) | 2004-06-18 | 2006-06-08 | Novartis Ag | AZA-BICYCLONONE COMPOUNDS AS CHOLINERGIC LINKS OF nAChR |
WO2006025071A1 (en) * | 2004-09-02 | 2006-03-09 | Natco Pharma Limited | A process for the preparation of escitalopram |
ITMI20041872A1 (en) | 2004-10-01 | 2005-01-01 | Adorkem Technology Spa | PROCESS FOR THE PREPARATION OF CITALOPRAM AND SCITALOPRAM |
WO2006106531A1 (en) * | 2005-04-04 | 2006-10-12 | Jubilant Organosys Ltd | Process for the preparation of escitalopram or its acid addition salts |
GB0507298D0 (en) | 2005-04-11 | 2005-05-18 | Novartis Ag | Organic compounds |
ITTO20050301A1 (en) * | 2005-05-05 | 2006-11-06 | Errekappa Euroterapici Spa | ORAL LIQUID FORMULATIONS CONTAINING CITALOPRAM |
WO2006123243A2 (en) * | 2005-05-20 | 2006-11-23 | Aurobindo Pharma Limited | Pharmaceutical dosage forms comprising escitalopram in form of granules |
TWI358407B (en) * | 2005-06-22 | 2012-02-21 | Lundbeck & Co As H | Crystalline base of escitalopram and orodispersibl |
JP2009515840A (en) * | 2005-11-14 | 2009-04-16 | ハー・ルンドベック・アクチエゼルスカベット | Manufacturing method of escitalopram |
GB0525673D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
GB0525672D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
GB0601286D0 (en) | 2006-01-23 | 2006-03-01 | Sandoz Ag | Asymmetric synthesis |
FR2912057B1 (en) * | 2007-02-07 | 2009-04-17 | Sanofi Aventis Sa | PHARMACEUTICAL COMPOSITION COMPRISING SAREDUTANT AND A SELECTIVE SEROTONIN RECAPTURE INHIBITOR OR SEROTONIN / NOREPINEPHRINE RECAPTURE INHIBITOR |
US20070259952A1 (en) * | 2006-05-02 | 2007-11-08 | H. Lundbeck A/S | Uses of escitalopram |
TW200817003A (en) * | 2006-07-31 | 2008-04-16 | Sanofi Aventis | Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor |
EP2086509A1 (en) * | 2006-10-20 | 2009-08-12 | Ratiopharm GmbH | Escitalopram and solid pharmaceutical composition comprising the same |
WO2008050673A1 (en) | 2006-10-27 | 2008-05-02 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive skin patch |
WO2008104880A2 (en) * | 2007-03-01 | 2008-09-04 | Aurobindo Pharma Limited | Stable solid dosage forms of an antidepressant |
WO2008142379A2 (en) | 2007-05-18 | 2008-11-27 | Cipla Limited | Process for the preparation of escitalopram via desmethylcitalopram, optical resolution and methylation of the s-isomer |
US20080312318A1 (en) * | 2007-06-14 | 2008-12-18 | Protia, Llc | Deuterium-enriched escitalopram |
EP2017271A1 (en) | 2007-07-06 | 2009-01-21 | Aurobindo Pharma Limited | Process for the preparation of escitalopram |
US20090048336A1 (en) * | 2007-08-17 | 2009-02-19 | Naveen Kumar Kolla | Escitalopram oxalate powders |
US8022232B2 (en) | 2007-09-11 | 2011-09-20 | H. Lundbeck A/S | Method for manufacture of escitalopram |
NZ570884A (en) | 2007-09-11 | 2010-03-26 | Lundbeck & Co As H | Fractionally crystallising 4-[4-(dimethyl amino)-1-(4'-fluorophenyl)-1-hydroxybutyI]-3-(hydroxymethyl)-benzonitrile and manufacturing escitalopram therefrom |
US9339500B2 (en) * | 2008-03-04 | 2016-05-17 | Intra-Cellular Therapies, Inc. | Methods of treating vasomotor symptoms |
CN101538257B (en) * | 2008-03-21 | 2012-10-17 | 浙江华海药业股份有限公司 | Method for preparing citalopram and S-citalopram |
CN101265215B (en) * | 2008-04-18 | 2011-03-16 | 浙江奥托康制药集团股份有限公司 | Method for preparing (S)-citalopram intermediate S-type glycol |
EP2291181B9 (en) | 2008-04-18 | 2013-09-11 | University College Dublin National University Of Ireland, Dublin | Captodiamine for the treatment of depression symptoms |
EP2116231A1 (en) | 2008-05-07 | 2009-11-11 | Hexal Ag | Granulate comprising escitalopram oxalate |
US20110230666A1 (en) * | 2008-06-03 | 2011-09-22 | Shodhana Laboratories Limited | process for the separation of enantiomerically pure compounds |
US20110092719A1 (en) * | 2008-06-16 | 2011-04-21 | Shodhana Laboratories Limited | Preparation of Escitalopram, Its Salts and Intermediates |
GR20080100696A (en) | 2008-10-23 | 2010-05-13 | Genepharm �.�. | Taste masked dosage form of pharmaceutically aceptable salt of escitalopram |
JP5740300B2 (en) * | 2009-02-27 | 2015-06-24 | 久光製薬株式会社 | Transdermal formulation |
CN102190600B (en) * | 2010-03-13 | 2015-04-15 | 浙江华海药业股份有限公司 | Preparation method of IV intermediate S-diol |
CN102757414B (en) * | 2011-04-25 | 2014-02-19 | 齐鲁制药有限公司 | Preparation method of eseitalopram oxalate |
WO2013081567A1 (en) | 2011-12-02 | 2013-06-06 | Mahmut Bilgic | Effervescent antipsychotic formulations |
WO2013100870A1 (en) | 2011-12-02 | 2013-07-04 | Mahmut Bilgic | New antipsychotic compositions |
ITMI20120105A1 (en) * | 2012-01-30 | 2013-07-31 | Carthesia S A S | AQUEOUS SOLUTION OF OXALED ESCITALOPRAM AND ITS USE |
CN104119248A (en) * | 2014-08-08 | 2014-10-29 | 广东东阳光药业有限公司 | Method for preparing S-citalopram |
WO2016074225A1 (en) * | 2014-11-14 | 2016-05-19 | 浙江华海药业股份有限公司 | Method for resolution of citalopram intermediate 5-cyanogen diol |
EP3309142B1 (en) | 2015-06-09 | 2020-08-05 | Zhejiang Huahai Pharmaceutical Co., Ltd | Method for preparing citalopram diol intermediate |
CN107311968A (en) * | 2016-03-31 | 2017-11-03 | 广州市恒诺康医药科技有限公司 | Citalopram handkerchief not hydrochlorate and its crystal habit and its production and use |
CN108976188B (en) * | 2017-06-05 | 2022-12-06 | 上海奥博生物医药股份有限公司 | Novel preparation method of escitalopram pamoate |
EP3694843B1 (en) | 2017-10-09 | 2022-01-26 | Hasleton, Mark | New salt and solid state forms of escitalopram |
CN111217777A (en) | 2018-11-26 | 2020-06-02 | 上海奥博生物医药技术有限公司 | Novel preparation process of high-purity escitalopram pamoate |
JP2022540706A (en) | 2019-07-19 | 2022-09-16 | バイオエクセル セラピューティクス,インコーポレイテッド | Nonsedating Dexmedetomidine Treatment Regimens |
KR102441089B1 (en) | 2020-06-15 | 2022-09-07 | 환인제약 주식회사 | A Pharmaceutical Composition |
WO2022153262A1 (en) | 2021-01-18 | 2022-07-21 | Anton Frenkel | Pharmaceutical dosage form |
US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4136193A (en) * | 1976-01-14 | 1979-01-23 | Kefalas A/S | Anti-depressive substituted 1-dimethylaminopropyl-1-phenyl phthalans |
US4650884A (en) * | 1984-08-06 | 1987-03-17 | H. Lundbeck A/S | Novel intermediate and method for its preparation |
-
1988
- 1988-06-14 GB GB888814057A patent/GB8814057D0/en active Pending
-
1989
- 1989-05-29 DK DK259989A patent/DK259989A/en not_active Application Discontinuation
- 1989-05-30 IL IL9046589A patent/IL90465A/en active Protection Beyond IP Right Term
- 1989-06-01 DE DE68921672T patent/DE68921672T2/en not_active Expired - Lifetime
- 1989-06-01 AT AT89305532T patent/ATE119896T1/en active
- 1989-06-01 EP EP89305532A patent/EP0347066B1/en not_active Expired - Lifetime
- 1989-06-01 DE DE2003199030 patent/DE10399030I2/en active Active
- 1989-06-01 ES ES89305532T patent/ES2068891T4/en not_active Expired - Lifetime
- 1989-06-06 NZ NZ229426A patent/NZ229426A/en unknown
- 1989-06-08 US US07/363,589 patent/US4943590A/en not_active Ceased
- 1989-06-08 FI FI892823A patent/FI98627C/en active Protection Beyond IP Right Term
- 1989-06-12 IE IE185989A patent/IE65734B1/en not_active IP Right Cessation
- 1989-06-13 ZA ZA894476A patent/ZA894476B/en unknown
- 1989-06-13 NO NO892447A patent/NO172892C/en not_active IP Right Cessation
- 1989-06-13 AU AU36295/89A patent/AU623144B2/en not_active Expired
- 1989-06-13 CA CA000602683A patent/CA1339452C/en not_active Expired - Lifetime
- 1989-06-14 JP JP1149752A patent/JP3044253B2/en not_active Expired - Lifetime
- 1989-06-14 PT PT90845A patent/PT90845B/en not_active IP Right Cessation
-
1992
- 1992-06-25 MX MX9203346A patent/MX9203346A/en unknown
-
1993
- 1993-02-01 DK DK011593A patent/DK170280B1/en not_active IP Right Cessation
- 1993-09-14 US US08/122,009 patent/USRE34712E/en not_active Expired - Lifetime
-
1994
- 1994-04-20 FI FI941829A patent/FI113762B1/en active
-
1995
- 1995-04-19 GR GR950401026T patent/GR3015889T3/en unknown
- 1995-06-28 HU HU95P/P00496P patent/HU211460A9/en unknown
-
1996
- 1996-07-25 HK HK139596A patent/HK139596A/en not_active IP Right Cessation
-
1997
- 1997-01-22 CA CA000617069A patent/CA1339568C/en not_active Expired - Lifetime
-
1998
- 1998-10-16 CY CY9802081A patent/CY2081B1/en unknown
-
1999
- 1999-02-24 JP JP11046008A patent/JP3038204B2/en not_active Expired - Lifetime
-
2000
- 2000-03-06 FI FI20000507A patent/FI20000507A/en unknown
-
2002
- 2002-11-26 NO NO2002014C patent/NO2002014I2/en unknown
-
2003
- 2003-01-15 LU LU90999C patent/LU90999I2/en unknown
-
2004
- 2004-07-13 NL NL300155C patent/NL300155I2/en unknown
- 2004-10-20 FI FI20041359A patent/FI20041359A/en not_active Application Discontinuation
-
2007
- 2007-01-29 CY CY200700004C patent/CY2007004I1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4136193A (en) * | 1976-01-14 | 1979-01-23 | Kefalas A/S | Anti-depressive substituted 1-dimethylaminopropyl-1-phenyl phthalans |
US4650884A (en) * | 1984-08-06 | 1987-03-17 | H. Lundbeck A/S | Novel intermediate and method for its preparation |
Cited By (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050101665A1 (en) * | 1999-07-08 | 2005-05-12 | H. Lundbeck A/S | Treatment of neurotic disorders |
US6960613B2 (en) | 1999-07-08 | 2005-11-01 | H. Lundbeck A/S | Treatment of neurotic disorders |
US7265151B2 (en) | 1999-07-08 | 2007-09-04 | H. Lundbeck A/S | Treatment of neurotic disorders |
US20040029956A1 (en) * | 1999-07-08 | 2004-02-12 | H. Lundbeck A/S | Treatment of neurotic disorders |
US20040167210A1 (en) * | 2000-03-13 | 2004-08-26 | Hans Petersen | Crystalline base of citalopram |
US20040132808A1 (en) * | 2000-03-13 | 2004-07-08 | Hans Petersen | Crystalline base of citalopram |
US20050165092A1 (en) * | 2000-03-13 | 2005-07-28 | H. Lundbeck A/S | Crystalline base of citalopram |
US6579993B2 (en) | 2001-01-30 | 2003-06-17 | Orion Corporation, Fermion | Process for the preparation of 1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile |
US6753433B2 (en) | 2001-01-30 | 2004-06-22 | Orion Corporation, Fermion | Process for the preparation of 1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile |
US20030130527A1 (en) * | 2001-01-30 | 2003-07-10 | Orion Corporation Fermion | Process for the preparation of 1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile |
US20040192766A1 (en) * | 2001-05-01 | 2004-09-30 | H. Lundbeck A/S | Use of enantiomeric pure escitalopram |
US20040192764A1 (en) * | 2001-05-01 | 2004-09-30 | H. Lundbeck A/S | Use of enantiomeric pure escitalopram |
US20040198811A1 (en) * | 2001-05-01 | 2004-10-07 | H. Lundbeck A/S | Use of enantiomeric pure escitalopram |
US20040198809A1 (en) * | 2001-05-01 | 2004-10-07 | Connie Sanchez | Use of enantiomeric pure escitalopram |
US7148364B2 (en) | 2002-01-07 | 2006-12-12 | Sun Pharmaceutical Industries | Process for the preparation of 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran carbonitrile |
US20050043550A1 (en) * | 2002-01-07 | 2005-02-24 | Thennati Rajamannar | Process for the preparation of 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran carbonitrile |
US20040009573A1 (en) * | 2002-01-30 | 2004-01-15 | Gary Strobel | Pestalotiopsis microsporia isolates and compounds derived therefrom |
US7192939B2 (en) | 2002-01-30 | 2007-03-20 | Montana State University | Pestalotiopsis microsporia isolates and compounds derived therefrom |
US7019153B2 (en) | 2003-06-10 | 2006-03-28 | Sun Pharmaceutical Industries Limited | Process for hydrogenolysis of [1-(3-dimethylamino)propyl)]-1-(4-fluorophenyl)-1,3-dihydro-5-halo-isobenzofuran acetamido-3-substituted-3-cephem-4-carboxylic acid |
US20070123584A1 (en) * | 2003-11-07 | 2007-05-31 | H. Lundbeck A/S | Method of treating premenstrual dysphoric disorder with escitalopram |
US20050101666A1 (en) * | 2003-11-07 | 2005-05-12 | H. Lundbeck A/S | Method of treating premenstrual dysphoric disorder with escitalopram |
US20050143350A1 (en) * | 2003-11-19 | 2005-06-30 | Seed John C. | Combination drug therapy to treat obesity |
US7582780B2 (en) | 2004-02-12 | 2009-09-01 | H. Lundbeck A/S | Method for the separation of intermediates which may be used for the preparation of escitalopram |
US20070190624A1 (en) * | 2004-02-12 | 2007-08-16 | H. Lundbeck A/S | Method for the separation of intermediates which may be used for the preparation of escitalopram |
US20050196453A1 (en) * | 2004-03-05 | 2005-09-08 | H. Lundbeck A/S | Crystalline composition containing escitalopram |
US7420068B2 (en) | 2004-03-05 | 2008-09-02 | H. Lundbeck A/S | Crystalline composition containing escitalopram |
US20060014957A1 (en) * | 2004-07-07 | 2006-01-19 | Pfizer Inc | Resolution of an aryl-fused azapolycyclic compound |
US20100249437A1 (en) * | 2004-08-23 | 2010-09-30 | Sun Pharma Global Fze | Process for preparation of citalopram and enantiomers |
EP2141156A1 (en) | 2004-08-23 | 2010-01-06 | Sun Pharma Global FZE | Process for Preparation of Citalopram and Enantiomers |
US7790935B2 (en) | 2004-08-23 | 2010-09-07 | Sun Pharma Global Fze | Process for preparation of citalopram and enantiomers |
US7964742B2 (en) | 2004-08-23 | 2011-06-21 | Sun Pharma Global Fze | Process for preparation of citalopram and enantiomers |
US7989645B2 (en) | 2004-08-23 | 2011-08-02 | Sun Pharma Global Fze | Process for preparation of citalopram and enantiomers |
WO2006021971A2 (en) | 2004-08-23 | 2006-03-02 | Sun Pharmaceutical Industries Limited | 'process for preparation of citalopram and enantiomers' |
US20080177096A1 (en) * | 2004-08-23 | 2008-07-24 | Sun Pharmaceutical Industries Ltd. | Process for preparation of citalopram and enantiomers |
US7368477B2 (en) | 2005-04-22 | 2008-05-06 | Wyeth | Benzofuranyl alkanamine derivatives and uses thereof |
US7402687B2 (en) | 2005-04-22 | 2008-07-22 | Wyeth | Dihydrobenzofuran derivatives and uses thereof |
US20060247276A1 (en) * | 2005-04-22 | 2006-11-02 | Wyeth | Benzofuranyl alkanamine derivatives and uses thereof |
US20060258739A1 (en) * | 2005-04-22 | 2006-11-16 | Wyeth | Dihydrobenzofuran derivatives and uses therof |
US20060258714A1 (en) * | 2005-04-22 | 2006-11-16 | Wyeth | Chromane and chromene derivatives and uses thereof |
US20080200541A1 (en) * | 2005-04-22 | 2008-08-21 | Wyeth | Benzofuranyl Alkanamine Derivatives and Uses Thereof |
US20080182891A1 (en) * | 2005-04-22 | 2008-07-31 | Wyeth | Chromane and chromene derivatives and uses thereof |
US7365095B2 (en) | 2005-04-22 | 2008-04-29 | Wyeth | Chromane and chromene derivatives and uses thereof |
US7560576B2 (en) | 2005-06-22 | 2009-07-14 | H. Lundbeck A/S | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base |
US20080161388A1 (en) * | 2005-06-22 | 2008-07-03 | H. Lundbeck A/S | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base |
US7834201B2 (en) | 2005-06-22 | 2010-11-16 | H. Lundbeck A/S | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base |
US20070021499A1 (en) * | 2005-06-22 | 2007-01-25 | H. Lundbeck A/S | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base |
US7723533B2 (en) | 2005-06-22 | 2010-05-25 | H. Lundbeck A/S | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base |
US20080161584A1 (en) * | 2005-06-22 | 2008-07-03 | H. Lundbeck A/S | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base |
US20090099375A1 (en) * | 2005-07-27 | 2009-04-16 | Vipin Kumar Kaushik | process for the preparation of escitalopram |
US7939680B2 (en) | 2005-07-27 | 2011-05-10 | Aurobindo Pharma Ltd. | Process for the preparation of Escitalopram |
US20070112075A1 (en) * | 2005-10-14 | 2007-05-17 | Forest Laboratories, Inc. | Stable pharmaceutical formulations containing escitalopram and bupropion |
US7569605B2 (en) | 2005-10-14 | 2009-08-04 | Forest Laboratories Holdings Limited | Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion |
US20070203231A1 (en) * | 2005-10-14 | 2007-08-30 | Forest Laboratories, Inc. | Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion |
US20070225279A1 (en) * | 2006-03-24 | 2007-09-27 | Wyeth | Therapeutic combinations for the treatment of depression |
US20080153927A1 (en) * | 2006-12-22 | 2008-06-26 | Allergan, Inc. | Alpha-2b receptor agonist and relaxant compositions for treating gastrointestinal motility disorders |
US20080153874A1 (en) * | 2006-12-22 | 2008-06-26 | Allergan Inc. | Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain |
US20080153832A1 (en) * | 2006-12-22 | 2008-06-26 | Allergan, Inc. | Pan-alpha-2 receptor agonist and relaxant compositions for treating gastrointestinal motility disorders |
US20080153825A1 (en) * | 2006-12-22 | 2008-06-26 | Allergan Inc. | Alpha-2b receptor agonist and 5ht4 serotonin receptor compositions for treating gastrointestinal motility disorders |
US20080153881A1 (en) * | 2006-12-22 | 2008-06-26 | Allergan, Inc. | Alpha-2b receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders |
US20080153808A1 (en) * | 2006-12-22 | 2008-06-26 | Allergan, Inc. | Alpha-2 receptor pan agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain |
US20080153880A1 (en) * | 2006-12-22 | 2008-06-26 | Allergan, Inc. | Pan-alpha-2 receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders |
EP1988086A1 (en) | 2007-04-23 | 2008-11-05 | Synthon B.V. | Process for resolving citalopram via its (S)-enriched citalopram tartrate compound. |
US20080281110A1 (en) * | 2007-04-23 | 2008-11-13 | Jie Zhu | Process for resolving citalopram |
US7566793B2 (en) | 2007-04-23 | 2009-07-28 | Synthon Bv | Process for resolving citalopram |
US20110015208A1 (en) * | 2007-08-03 | 2011-01-20 | Gary Samoriski | Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands |
US20090036468A1 (en) * | 2007-08-03 | 2009-02-05 | Forest Laboratories Holdings Limited | Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands |
US20100249438A1 (en) * | 2009-03-30 | 2010-09-30 | Vijaya Bhaskar Bolugoddu | Preparation of escitalopram |
US8829020B2 (en) | 2009-07-16 | 2014-09-09 | Mallinckrodt Llc | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers |
US9518062B2 (en) | 2009-07-16 | 2016-12-13 | Mallinckrodt Llc | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers |
US9527858B2 (en) | 2009-07-16 | 2016-12-27 | Mallinckrodt Llc | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers |
WO2013114416A1 (en) | 2012-01-30 | 2013-08-08 | Carthesia S.A.S. | Lyophilized tablets of escitalopram oxalate for sublingual administration |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE34712E (en) | Pharmaceutically useful (+)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroiso benzofuran-5-carbonitrile and non-toxic acid addition salts thereof | |
AU738359B2 (en) | Method for the preparation of citalopram | |
AU759716B2 (en) | Method for the preparation of citalopram | |
US20010031784A1 (en) | Crystalline base of citalopram | |
AU2001100271A4 (en) | Method for the preparation of citalopram | |
US20020077353A1 (en) | Method for the preparation of citalopram | |
EA001728B1 (en) | Method for the praparation of citalopram | |
US20030083508A1 (en) | Method for the preparation of citalopram | |
JP4377219B2 (en) | Process for producing racemic citalopram and S- or R-citalopram by separating a mixture of R- and S-citalopram | |
US20060189816A1 (en) | Product |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FPAY | Fee payment |
Year of fee payment: 12 |
|
PTEF | Application for a patent term extension |
Free format text: PRODUCT NAME: LEXAPRO (ESCITALOPRAM OXALATE); REQUESTED FOR 827 DAYS Filing date: 20021011 Expiry date: 20090608 |
|
PTEG | Grant of a patent term extension |
Free format text: PRODUCT NAME: LEXAPRO (ESCITALOPRAM OXALATE) Filing date: 20021011 Expiry date: 20090608 |